InNexus Biotechnology, Inc.

As of March 31, 2011, InNexus Biotechnology, Inc. has 163.20M shares outstanding.

These figures are as of March 31, 2011.

As of March 31, 2011, InNexus Biotechnology, Inc. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -104.61, indicating conservative leverage, while an interest coverage ratio of -0.64 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2011. Return on assets (ROA) is negative at -117.44, reflecting losses generated across the asset base.

These figures cover the twelve months ended March 31, 2011. Free cash flow yield is negative at -8.13: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.86, meaning InNexus Biotechnology, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2011, InNexus Biotechnology, Inc. has an Altman Z-Score of -116.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.